Analyst Conference Call Notes by William Meyers

Biotechnology Investor Aids


conference date: March 27, 2018 @ 8:00 AM Pacific Time

Independent NIH Analysis of Thermodox plus RFA for Liver Cancer [September 12, 2016]

RFA plus lyso-thermosensitive liposomal doxorubicin [June 10, 2016] all the details on Thermodox studies

May 12, 2017
August 15, 2017
Nov. 14, 2017
March 27, 2018

Celsion (CLSN) is a clinical-stage biotechnology company specializing in cancer therapies. Its lead product is ThermoDox for liver cancer.

Celsion web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers